GHK-Cu: Forty Years of Research on a Three-Amino-Acid Copper Peptide

GHK is a tripeptide composed of glycine, L-histidine, and L-lysine. It was first isolated from human plasma by Loren Pickart in 1973 and described as a factor that improved the growth of cultured hepatocytes from older donors. When complexed with divalent copper, the resulting GHK-Cu has been studied for over four decades for effects on skin, hair, connective tissue, wound healing, and broad patterns of gene expression. Few peptides have such a long and consistent research record.

GHK binds copper(II) with exceptionally high affinity, and the copper-binding chemistry is central to most of its proposed biological activity. The peptide is found endogenously in human plasma, saliva, and urine, with concentrations that decline with age — a correlation that has driven much of the interest in supplementing it as a research tool.

GHK-Cu's mechanisms span several systems. In dermatological research, it has been characterized for stimulation of fibroblast proliferation, increased collagen and glycosaminoglycan synthesis, and modulation of metalloproteinases involved in tissue remodeling. In wound-healing models, it has demonstrated effects on angiogenesis, recruitment of immune cells, and accelerated closure in both rodent and porcine systems.

The broadest claim about GHK-Cu comes from gene-expression studies. Using the Connectivity Map (CMap) data set, Pickart and Margolina analyzed GHK's effect on gene transcription and reported that the peptide modulates a large number of human genes — including those involved in DNA repair, antioxidant defense, and tissue remodeling — in directions associated with a 'younger' transcriptional profile. The 2018 review in International Journal of Molecular Sciences synthesizes this and the surrounding mechanistic literature.

GHK-Cu is one of the few peptides in this catalog with a long history of inclusion in topical cosmetic formulations, where it has been studied for effects on skin appearance, fine lines, hyperpigmentation, and hair-follicle biology. Several controlled clinical studies — typically small, often industry-sponsored — have reported measurable improvements in skin laxity and density with topical GHK-Cu formulations applied over weeks.

Researchers should note that topical and systemic delivery are not equivalent: most of the human evidence base is topical, and extrapolation to other administration routes is not supported by controlled clinical data.

GHK-Cu is supplied lyophilized as the copper-bound complex, typically with a distinctive blue color from the copper(II) ion. The peptide is sensitive to reducing agents, which can dissociate the copper complex, and should be kept away from materials that might compete for copper binding.

Stock material is typically stored at -20°C, dry and protected from light. This product is supplied for in vitro and preclinical research use only. It is not sold for human consumption and has not been approved by the FDA for any therapeutic indication.

What sets GHK-Cu apart in the broader peptide landscape is the depth and consistency of its mechanistic literature across independent research groups, the unusually long observation period (over four decades), and the chemistry of its copper-binding behavior, which gives it a defined and reproducible molecular fingerprint. For researchers interested in copper-peptide biology, tissue remodeling, or small-peptide gene-expression effects, GHK-Cu remains the most thoroughly characterized reference molecule in its class.